Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2025) 146 (Supplement 1): 5311.

https://doi.org/10.1182/blood-2025-5311

Published: 2025

Journal Articles

Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma

Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2025) 146 (Supplement 1): 1756.

https://doi.org/10.1182/blood-2025-1756

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Won-Seog Kim, Dok Hyun Yoon, Youngil Koh, Seok Jin Kim, Sang Eun Yoon, Hyungwoo Cho, Jaewon Hyung, Ja Min Byun, Hyesung Jeon, Seungryel Han

Blood (2025) 146 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2025-1043

Published: 2025

Journal Articles

Prognostic value of mayo 2012 vs. european‑modified mayo 2004 staging in AL amyloidosis patients with discordant stage classifications

Miran Han, Sang Eun Yoon, Seokjin Kim, Darae Kim, Jin-Oh Choi, Jung Eun Lee, Jung-Sun Kim, Ju-Hong Min, Byoung Joon Kim, Kihyun Kim

Blood (2025) 146 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2025-5738

Published: 2025

Journal Articles

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Won Seog Kim, Seok Jin Kim, Jae-Cheol Cho, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Heung Tae Kim

Blood (2025) 146 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2025-5426

Published: 2025

Journal Articles

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Deok-Hwan Yang, Sung Yong Oh, Youngwoo Jeon, Ga-Young Song, Seokjin Kim, Sang Eun Yoon, Tong-Yoon Kim, Ji Hyun Lee, Hye Ryeon Kim, Youngil Koh, Han Song, Myungsea Lee, Won Seog Kim

Blood (2025) 146 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2025-5463

Published: 2025

Journal Articles

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Dong Hyun Kim, Sanyeowool An, Ka-Won Kang, Sang Eun Yoon, Seok Jin Kim, Hyo Jung Kim, Youngil Koh, Deok-Hwan Yang

Blood (2025) 146 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2025-3692

Published: 2025

Journal Articles

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Blood (2025) 146 (2): 155–166.

https://doi.org/10.1182/blood.2024027109

Published: 2025

Includes: Supplemental data

Journal Articles

The Reason Why We Should Differentiate Monomorphic Epitheliotropic T Cell Lymphoma and Intestinal T Cell Lymphoma, NOS - a Retrospective Study about the Experience of a Single Tertiary Hospital in Korea

Jiyeon Hyeon, Changgon Kim, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Junhun Cho, Won Seog Kim

Blood (2024) 144 (Supplement 1): 6419.

https://doi.org/10.1182/blood-2024-210911

Published: 2024

Journal Articles

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Sang Eun Yoon, Sung-Hoon Jung, Gyeong Won Lee, Chang-Ki Min, Ja Min Byun, Jae-Yong Kwak, Myung-Won Lee, Ho Sup Lee, Seok Jin Kim, Kihyun Kim

Blood (2024) 144 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2024-198947

Published: 2024

Journal Articles

Integrated Omics to Dissect the Landscape in Chemosensitive and Refractory Extranodal Natural-Killer T-Cell Lymphoma (ENKTCL): A Global Study of the PETAL (PEripheral T-Cell Lymphoma) Consortium

Blood (2024) 144 (Supplement 1): 6207.

https://doi.org/10.1182/blood-2024-208838

Published: 2024

Journal Articles

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Jordan S Goldstein, Mark Roschewski, Won-Seog Kim, Sang Eun Yoon, Seok Jin Kim, Jason R. Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob Chabon, Davide Rossi, Wyndham H. Wilson, David Kurtz, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 651.

https://doi.org/10.1182/blood-2024-211068

Published: 2024

Journal Articles

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Mark N Sorial, Sean M McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. J. Fernandez Turizo, Caroline MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra W Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven Horwitz, Mwanasha H. Merrill, Eric D. Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie G Ford, Martina Manni, Monica Civallero, Tetiana Skrypets, Massimo Federico, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2024) 144 (Supplement 1): 465.

https://doi.org/10.1182/blood-2024-201874

Published: 2024

Journal Articles

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (6): 629–638.

https://doi.org/10.1182/blood.2023023419

Published: 2024

Includes: Supplemental data

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Journal Articles

Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients

Sang Eun Yoon, Woorim Kang, Junhun Cho, Jiyeon Hyeon, Seok Jin Kim, Won Seog Kim

Blood (2023) 142 (Supplement 1): 5728.

https://doi.org/10.1182/blood-2023-173788

Published: 2023

Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim

Blood (2023) 142 (Supplement 1): 69.

https://doi.org/10.1182/blood-2023-187650

Published: 2023

Journal Articles

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

YoungJu PARK, Juhee Cho, Sooyeon Kim, Kihyun Kim, Sang Eun Yoon, Danbee Kang, Garam Bang, Nayeon Kim, Jeong Hyun Park, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 5088.

https://doi.org/10.1182/blood-2023-178418

Published: 2023

Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz

Blood (2023) 142 (Supplement 1): 187.

https://doi.org/10.1182/blood-2023-187759

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Prognostic value of mayo 2012 vs. european‑modified mayo 2004 staging in AL amyloidosis patients with discordant stage classifications

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

The Reason Why We Should Differentiate Monomorphic Epitheliotropic T Cell Lymphoma and Intestinal T Cell Lymphoma, NOS - a Retrospective Study about the Experience of a Single Tertiary Hospital in Korea

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Integrated Omics to Dissect the Landscape in Chemosensitive and Refractory Extranodal Natural-Killer T-Cell Lymphoma (ENKTCL): A Global Study of the PETAL (PEripheral T-Cell Lymphoma) Consortium

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only